TEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Teva Pharmaceutical Industries Ltd's research and development for the three months ended in Mar. 2016 was $389 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2016 was $1,582 Mil.
This is the expense the company spent on research and development.
Teva Pharmaceutical Industries Ltd Research & Development for the trailing twelve months (TTM) ended in Mar. 2016 was 386 (Jun. 2015 ) + 361 (Sep. 2015 ) + 446 (Dec. 2015 ) + 389 (Mar. 2016 ) = $1,582 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Teva Pharmaceutical Industries Ltd Annual Data
|Research & Development||495||581||2,188||802||933||1,095||1,356||1,427||1,488||1,525|
Teva Pharmaceutical Industries Ltd Quarterly Data
|Research & Development||411||353||344||412||379||332||386||361||446||389|